Activity of matrix metalloproteinase type 9 and its relationship with calcification of the thoracic aorta in patients with resistant hypertension: cross-sectional comparative study

Cover Page

Cite item

Full Text

Abstract

Background. The extracellular matrix of vessels is degraded under the influence of matrix metalloproteinases (MMPs). MMP type 9 is of particular interest in arterial hypertension (AH) since its activity is regulated by a tissue inhibitor of matrix metalloproteinase type 1 (TIMP1). The balance of their ratio can shift in either direction depending on the disease stage and provoke vascular wall calcification.

Objective. This cross-sectional comparative study investigated the level of MMP9 and its type 1 tissue inhibitor and their relationship with the severity of thoracic aorta calcification in patients with resistant hypertension, depending on antihypertensive therapy effectiveness.

Material and methods. The study included 92 patients with resistant hypertension. All patients underwent 24-hour blood (BP) pressure monitoring (ABPM), and had their index of the thoracic aorta (ТАС) and the plasma levels of MMP9 and TIMP1 assessed.

Results. Patients were divided into groups based on whether they achieved the BP target level according to the results of ABPM: controlled (n=44) and uncontrolled (n=48) resistant AH. In the second group, most estimated parameters of ABPM were higher, and the variants of the daily BP profile for non-dipper and night-peaker systolic blood pressure (SBP) were more common than in the first group. In the second group, a more pronounced increase in TAC, TIMP1, and TIMP1/MMP9 levels was revealed. Evaluation of the relationship between the studied parameters revealed a positive relationship between TAC and age (r=0.683, p <0.00001), hypertension duration (r=0.610, p <0.00001) and a negative relationship with regular antihypertensive therapy duration (r=0.822, p <0.00001). ТАC was higher in individuals with higher values of SBP (r=0.513, р <0.00001), pulse BP (r=0.805, р <0.00001), rate of morning rise in BP (r=0.678, р <0.00001) and insufficient decrease in SBP at night (r=-0.822, р <0.00001). There was a positive correlation of moderate strength TAC with the level of low-density lipoproteins (r=0.490, p=0.0002), TIMP1 (r=0.344, p=0.005) and the TIMP1/MMP9 ratio (r=0.481, p <0.00001).

Conclusion. In patients with resistant hypertension, an increase in the TAC was revealed, which has a statistically significant direct correlation with the value of pulse BP, the morning rise in BP, and an insufficient decrease in SBP at night. An imbalance in the TIMP1/MMP9 ratio, rather than an isolated increase in MMP9, can indicate the intensity of the formation and degradation of the extracellular matrix components in patients with resistant AH, which triggers the vascular wall calcification process.

About the authors

Marina S. Litvinova

Rostov State Medical University; Clinical Diagnostic Center «Health»

Email: litvinova.m.803@mail.ru
ORCID iD: 0000-0003-2904-0914

cardiologist

Russian Federation, Rostov-on-Don; Rostov-on-Don

Larisa A. Khaisheva

Rostov State Medical University

Email: katelnitskay@mail.ru
ORCID iD: 0000-0002-2419-4319

MD, D. Sci. (Med.), Prof.

Russian Federation, Rostov-on-Don

Sergey V. Shlyk

Rostov State Medical University

Email: sshlyk@mail.ru
ORCID iD: 0000-0003-3070-8424

MD, D. Sci. (Med.), Prof., rector

Russian Federation, Rostov-on-Don

Igor A. Aboyan

Clinical Diagnostic Center «Health»

Author for correspondence.
Email: kdc@center-zdorovie.ru
ORCID iD: 0000-0002-2798-368X

MD, D. Sci. (Med.), Prof., chief physician

Russian Federation, Rostov-on-Don

References

  1. Reznik EV, Nikitin IG. New АСС/AHA and ESC/ESH arterial hypertension guidelines. Cardiovascular Therapy and Prevention. 2018;17(5):99–119. (In Russ). doi: 10.15829/1728-8800-2018-5-99-119
  2. Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ). doi: 10.15829/1560-4071-2020-3-3786
  3. Lamirault G, Artifoni M, Daniel M, et al. Resistant Hypertension: Novel Insights. Curr Hypertens Rev. 2020;16(1):61–72. doi: 10.2174/1573402115666191011111402
  4. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke Statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. doi: 10.1161/CIR.0000000000000558
  5. Humphrey JD. Mechanisms of Vascular Remodeling in Hypertension. Am J Hypertens. 2021;34(5):432–441. doi: 10.1093/ajh/hpaa195
  6. Tikhaeva KYu, Rogova LN, Tkachenko LV. The role of metalloproteinases in the exchange of endometrial extracellular matrix proteins in normal and patholog-ical conditions. Russian Journal of Human Reproduction. 2020;26(4):22–29. (In Russ). doi: 10.17116/repro20202604122
  7. Ruddy JM, Akerman AW, Kimbrough D, et al. Differential hypertensive protease expression in the thoracic versus abdominal aorta. J Vasc Surg. 2017;66(5):1543–1552. doi: 10.1016/j.jvs.2016.07.120
  8. Valente FM, de Andrade DO, Cosenso-Martin LN, et al. Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis. BMC Cardiovasc Disord. 2020;20(1):132. doi: 10.1186/s12872-020-01412-5
  9. Mashaqi S, Mansour HM, Alameddin H, et al. Matrix metalloproteinase-9 as a messenger in the cross talk between obstructive sleep apnea and comorbid systemic hypertension, cardiac remodeling, and ischemic stroke: a literature review. J Clin Sleep Med. 2021;17(3):567–591. doi: 10.5664/jcsm.8928
  10. Radosinska J, Barancik M, Vrbjar N. Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med. 2017;59(3):241–253. doi: 10.23736/S0031-0808.17.03321-3
  11. Chen Y, Waqar AB, Nishijima K, et al. Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits. J Cell Mol Med. 2020;24(7):4261–4274. doi: 10.1111/jcmm.15087
  12. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, et al. Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. Nefrologia (Engl Ed). 2019;39(2):184–191. doi: 10.1016/j.nefro.2018.08.009
  13. Prado AF, Batista RIM, Tanus-Santos JE, Gerlach RF. Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations. Biomolecules. 2021;11(4):585. doi: 10.3390/biom11040585
  14. Zhang Y, Lacolley P, Protogerou AD, Safar ME. Arterial Stiffness in Hypertension and Function of Large Arteries. Am J Hypertens. 2020;33(4):291–296. doi: 10.1093/ajh/hpz193
  15. Yanagisawa H, Yokoyama U. Extracellular matrix-mediated remodeling and mechanotransduction in large vessels during development and disease. Cell Signal. 2021;86:110104. doi: 10.1016/j.cellsig.2021.110104
  16. Poredos P, Poredos P, Jezovnik MK. Structure of Atherosclerotic Plaques in Different Vascular Territories: Clinical Relevance. Curr Vasc Pharmacol. 2018;16(2):125–129. doi: 10.2174/1570161115666170227103125
  17. Aksel'rod AS. Pokazateli SMAD v prakticheskoi i issledovatel'skoi kardiologii [Internet]. SCHILLER Russia [cited 08 February 2023]. Available from: https://www.schiller.ru/profile/articles/smad/146/. (In Russ).
  18. Lu J, Hao J, Du H, et al. Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats. Cell Physiol Biochem. 2016;39(1):47–60. doi: 10.1159/000445604
  19. Larina VN, Fedorova EV, Kulbachinskaya OM. Morning Blood Pressure Surge: a Review of National and Foreign Literature. Lechebnoe delo. 2019;3:66–73. (In Russ). doi: 10.24411/2071-5315-2019-12143
  20. Polonsky TS, Bakris GL. Ambulatory Blood Pressure Monitoring. JAMA. 2018;320(17):1807–1808. doi: 10.1001/jama.2018.14856
  21. Kario K. Nocturnal Hypertension: New Technology and Evidence. Hypertension. 2018;71(6):997–1009. doi: 10.1161/HYPERTENSIONAHA.118.10971
  22. Sogunuru GP, Kario K, Shin J, et al. Morning surge in blood pressure and blood pressure variability in Asia: Evidence and statement from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2019;21(2):324–334. doi: 10.1111/jch.13451
  23. Chiriacò M, Pateras K, Virdis A, et al. Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(12):2587–2598. doi: 10.1111/dom.13828
  24. Cardoso CRL, Salles GF. Associations of the nocturnal blood pressure fall and morning surge with cardiovascular events and mortality in individuals with resistant hypertension. J Hypertens. 2021;39(6):1177–1187. doi: 10.1097/HJH.0000000000002775
  25. Moon I, Jin KN, Kim HL, et al. Association of arterial stiffness with aortic calcification and tortuosity. Medicine (Baltimore). 2019;98(33):e16802. doi: 10.1097/MD.0000000000016802
  26. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta. 2012;413(7–8):656–662. doi: 10.1016/j.cca.2011.12.021
  27. Dellalibera-Joviliano R, Jacob-Ferreira AL, Joviliano EE, et al. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans. Vasc Med. 2012;17(2):73–78. doi: 10.1177/1358863X11435979
  28. Sengupta S, Addya S, Biswas D, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in murine β-coronavirus-induced neuroinflammation. Virology. 2022;566:122–135. doi: 10.1016/j.virol.2021.11.012
  29. Lacerda L, Faria AP, Fontana V, et al. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension. Arq Bras Cardiol. 2015;105(2):168–175. doi: 10.5935/abc.20150060
  30. Obisesan OH, Osei AD, Berman D, et al. Thoracic Aortic Calcium for the Prediction of Stroke Mortality (from the Coronary Artery Calcium Consortium). Am J Cardiol. 2021;148:16–21. doi: 10.1016/j.amjcard.2021.02.038
  31. Hermann DM, Lehmann N, Gronewold J, et al. Thoracic aortic calcification is associated with incident stroke in the general population in addition to established risk factors. Eur Heart J Cardiovasc Imaging. 2015;16(6):684–690. doi: 10.1093/ehjci/jeu293

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Daily systolic BP index in individuals with controlled and uncontrolled resistant hypertension.

Download (73KB)

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies